
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
SalioGen Therapeutics
Company Type: Therapeutic development
Main focus: Developing new therapeutics using their novel Gene Coding™ technology
Company stage: Pre-clinical
Diseases: Diseases of the eye/retina, ears, lungs, brain/CNS, and certain cancers
Genome-editing tool: Saliogase™ enzyme
Funding stage: Series B
Location: Lexington, Massachusetts, USA
Website: https://www.saliogen.com/
Pipeline: https://www.saliogen.com/pipeline/
Partners:

SalioGen Therapeutics is a biotechnology company that focuses on developing advanced gene therapy solutions. They specialise in a proprietary platform called Gene Coding™, which aims to provide durable and safe treatments for a variety of genetic diseases through insertion of large or multiple whole genes into the genome at specific locations via transposition using a bioengineered enzyme, Saliogase™.